AmphoTLC™ Lifts Off for Delivery to Indiaダウンロード
TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, is delivering its promise to help India with 18,760 vials of AmphoTLC™ to help fulfill the urgent unmet need for liposomal amphotericin B, putting the words “TLC is helping” into action.
Following a recent new drug registration with India’s Central Drugs Standard Control Organization (CDSCO), TLC entered separate non-exclusive commercialization agreements with Zydus Healthcare Limited (Zydus, part of Zydus Cadila) and Strides Pharma Science Limited (Strides) for immediate importation of its liposomal amphotericin B product as per approved usage and indication, for Zydus and Strides to market and sell in India. Today, TLC has shipped 10,670 vials to Zydus and 8,000 vials to Strides; the shipment to Zydus will arrive in Mumbai shortly after midnight on May 31, and the shipment to Strides is expected to arrive in Bengaluru in the evening of the same day.
“I continue to be amazed at the speed at which this nearly impossible mission has been made possible with the keen involvement of the TLC team, the Taiwan Food and Drug Administration, our Contract Manufacturing Organization and Taiwan distributor Yung Shin Pharmaceuticals, and Marken Taiwan Ltd. None of this would have been possible without the help of this elite team,” commented George Yeh, President of TLC. “What our corporate tagline – Delivering Hope for Life™ – delivers is so much more than hope; it is to deliver life-saving, efficacious and safe medicines to those in need.”